SCHEMBL2377085

SCHEMBL2377085

COc1ccc(CN(Cc2ccc(OC)cc2)c2ncc(B3OC(C)(C)C(C)(C)O3)c(OC)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 1/20 0.42
LMNA P02545 4/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 4/20 0.36
PIK3CA P42336 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 1/20 0.35
CHRM2 P08172 1/20 0.35
CYP3A4 P08684 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
DRD1 P21728 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
SLC6A4 P31645 1/20 0.35
CYP2C19 P33261 1/20 0.35
HRH1 P35367 1/20 0.35
OPRM1 P35372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2377518 0.89 UCHL1 (0.44) UCHL1LMNAMAPTALDH1A1PIK3CA
SCHEMBL2376356 0.82 LMNA (0.47) UCHL1LMNAMAPTALDH1A1PIK3CA
SCHEMBL15535603 0.78 ALPL (0.34) UCHL1MAPT
SCHEMBL29903798 0.75 LMNA (0.47) LMNAMAPTALDH1A1PIK3CACYP1A2
SCHEMBL26977577 0.75 LMNA (0.47) LMNAMAPTALDH1A1PIK3CACYP1A2
SCHEMBL26977590 0.75 LMNA (0.47) LMNAMAPTALDH1A1PIK3CACYP1A2
SCHEMBL30559715 0.73 LMNA (0.45) LMNAMAPTALDH1A1PIK3CACYP1A2
SCHEMBL26980527 0.73 LMNA (0.48) LMNAMAPTALDH1A1PIK3CACYP1A2
SCHEMBL26977534 0.73 LMNA (0.42) LMNAMAPTALDH1A1PIK3CACYP1A2
SCHEMBL15148374 0.73 MDM2 (0.32) UCHL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744661-A2 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2026-05-20 EP disclosed
US-20260027104-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2026-01-29 US disclosed
WO-2025243044-A1 COMPOUNDS Pheno Therapeutics Limited (GB) 2025-11-27 WO disclosed
EP-4298092-B1 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-11-26 EP disclosed
EP-4562003-A1 NOVEL 7-SUBSTITUTED INDOLE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-04 EP disclosed
EP-4562004-A1 NOVEL 7-SUBSTITUTED INDOLE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-04 EP disclosed
EP-4558479-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-05-28 EP disclosed
EP-4558498-A1 NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-05-28 EP disclosed
WO-2024023128-A1 NOVEL 7-SUBSTITUTED INDOLE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-02-01 WO disclosed
WO-2024023129-A1 NOVEL 7-SUBSTITUTED INDOLE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-02-01 WO disclosed
WO-2024017858-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
US-20240025883-A1 PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-01-25 US disclosed
WO-2024017857-A1 NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
WO-2024017858-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-01-25 WO disclosed
EP-4298092-A1 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-01-03 EP disclosed
WO-2022180136-A1 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2022-09-01 WO disclosed
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 UCHL1 4591/4885LMNA 4407/4885MAPT 4385/4885
US-20260027104-A1 NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES CBR3, HAX1, CBR1 UCHL1 4164/4885LMNA 1245/4885MAPT 4870/4885
US-20240025883-A1 PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES GPR17, GPR27, GPR119 UCHL1 4866/4885LMNA 3569/4885MAPT 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.